Insight on Pharmaceuticals and Healthcare in United Kingdom

Published within

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

Type Product title / description Pub Price
Report
Report

R&D Trends: Non-Insulin Antidiabetics - What opportunities remain for the vast pipeline in the crowded diabetes market?

Datamonitor module assesses the current state of the non-insulin antidiabetics pipeline and trends in clinical trial design and treatment that will shape its future. Focused on the US, Japan, France, Germany, Italy, Spain, and the UK

Published By Datamonitor
08 Jul 2011 $2800
Buy
Report
Report

R&D Trends: Breast Cancer - Innovative approaches target key signaling pathways in breast tumors

Review of key R&D trends in breast cancer including; dynamics of the pipeline, comparator therapies, target product profile, trends in clinical trial design, innovative early-stage projects, and the future of breast cancer treatment.

Published By Datamonitor
11 Jul 2011 $2800
Buy
Report
Report

R&D Trends: Neuropathic Pain - Extensive and diverse pipeline driven by high unmet need

This report reviews the key trends in the drug development pipeline for neuropathic pain. It also includes detailed analysis of clinical trial design, target product profile, innovative early-stage projects, and future treatments.

Published By Datamonitor
13 Jul 2011 $2800
Buy
Report
Report

Hot Topics in Type 2 Diabetes: Physician Perceptions of Incretin Mimetics and TZDs – Physician survey provides insights into TZD, DPP-IV, and GLP-1 usage

Datamonitor presents physician primary research on incretin mimetics and TZDs in the type 2 diabetes treatment algorithm, including patient share by class, brand splits, and trends. Focused on the US, Japan, France, Germany, Italy, Spain, and the UK.

Published By Datamonitor
15 Jul 2011 $2800
Buy
Report
Report

Product Profiles: Obesity - Pipeline stalls as regulatory requirements escalate

Datamonitor module assesses the current state of the obesity pipeline and trends that will shape its future. Focused on the US, Japan, France, Germany, Italy, Spain, and the UK

Published By Datamonitor
19 Jul 2011 $6400
Buy
Report
Report

Epidemiology: Benign Prostatic Hyperplasia – Expected to continue growing as the male population ages

Overview of benign prostatic hyperplasia definitions and a review of epidemiology literature. This module provides analysis of patient populations, a 10-year prevalent case forecast, and key patient segmentations across the seven major markets.

Published By Datamonitor
22 Jul 2011 $2800
Buy
Report
Report

Prescribing Influences: Allergic Rhinitis – Treatment tolerability remains a key differentiator

In March 2011, Datamonitor surveyed 149 ENT and allergy specialists and pulmonologists in the seven major markets. The results are analyzed with key opinion leader interviews and secondary sources to assess allergic rhinitis prescribing influences.

Published By Datamonitor
25 Jul 2011 $2800
Buy
Report
Report

Treatment Algorithms: Type 2 Diabetes – Novel classes drive fragmentation of treatment choices in type 2 diabetes

Datamonitor reports average patient population and prescribing behavior by therapy line in the seven major markets, as well as analysis of therapy switching, patient share by drug class, and class use trends, based on a 199-physician survey.

Published By Datamonitor
27 Jul 2011 $4800
Buy
Report
Report

Hot Topics: Obesity – Three Complete Response Letters and one Advisory Committee meeting

This case study explores the clinical and commercial ramifications of US Food & Drug Administration Complete Response Letters issued to Vivus, Arena and Orexigen, the sponsors of late stage obesity drugs Qnexa, Lorquess and Contrave.

Published By Datamonitor
27 Jul 2011 $2800
Buy
Report
Report

Hot Topics: Obesity – The US FDA and cardiovascular risk analysis: the AdComm Cometh

A US FDA obesity drug cardiovascular safety advisory committee meeting mooted for 2012 means obesity drug safety requirements could change dramatically. Two years after a similar scene in diabetes, this analysis profiles some pertinent precedents.

Published By Datamonitor
27 Jul 2011 $2800
Buy

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

No help is available.